Actinium’s stock jumps 22% on new data for its acute myeloid leukemia therapy


Shares of Actinium Pharmaceuticals Inc. ATNM, +29.87% were up 22.8% in trading on Monday after the company met the primary endpoint in a Phase 3 clinical trial for its investigational treatment for relapsed or refractory acute myeloid leukemia. Actinium said it plans to share additional clinical data by the end of the year. The company’s stock has soared 99.1% this year, while the S&P 500 SPX, -0.72% is down 18.5%. pt the field of bone marrow conditioning with Iomab-B, first in r/r AML and then by building upon its robust prior clinical results in several hematological diseases. We look forward to sharing additional clinical data from the SIERRA trial by year end.” fdsup://factset/Doc%20Viewer%20Single?_expand=oV0Mn8&float_window=true

This article was originally published by Read the original article here.

Previous articleDeep Dive: Municipal bond yields are attractive now — here’s how to figure out if they are right for you
Next articleBiden to accuse oil companies of refusing to ‘help lower prices at the pump’


Please enter your comment!
Please enter your name here